Treatment of severe ROP is evolving with the use of anti-angiogenic agents that inhibit the bioactivity of vascular endothelial growth factor (VEGF) instead of standard care laser photocoagulation of the peripheral avascular retina4. Here, VEGFA is linked to retinopathy of prematurity.